Results 191 to 200 of about 541,619 (302)

ANXA2‐mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo   +13 more
wiley   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

open access: yesAdvanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther   +13 more
wiley   +1 more source

Dumbbell‐Structured Plasmonic‐Enhanced Optical Nanoprobes Boosting Photo‐Magnetic‐Acoustic Multimodal Imaging‐Guided Photodynamic‐Photothermal Synergistic Treatment and Immunogenic Death in Nasopharyngeal Carcinoma

open access: yesAdvanced Science, EarlyView.
This study reports a novel rationally‐designed optical nanoprobe based on dumbbell‐shaped mesoporous silica‐coated gold nanorods, loaded with rare‐earth oxides, photosensitizers, and tumor‐targeted peptides, enabling plasmonic‐enhanced multimodal imaging and PTT‐PDT synergy.
Baikang Zhuang   +12 more
wiley   +1 more source

Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis. [PDF]

open access: yesJ Clin Med
Parisio L   +8 more
europepmc   +1 more source

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy